2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧49 min
8,00 NOK/osake
Viimeisin osinko
3,43%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 23.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·23 t sittenI have been following Medistim for a while. I once shared my fundamental analysis here on May 18 (see at the bottom of the posts). In my fundamental analysis, I applied Warren Buffett-inspired criteria for a healthy and profitable company. Medistim was the only one among all listed companies in the Nordics that met the criteria. Once again, after the Q2 report, we have the evidence that Medistim is a true quality company that hasn't been fully discovered yet, but it's only a matter of time. I went through the fresh report, and here is my new analysis: 1. Q2 result Revenue: 202 mill. (169.1) -> +19.5 % (Currency-adjusted revenue growth: +27.5 %) EBIT: 65.3 mill. (54.1) -> +20.6 % EBIT margin: 32.3 % Profit after tax: 52.2 mill.(42.9) -> +21.6 % EPS: 2.85 kr Gross margin: 82.2 % - My comment: For every 100 kroner in revenue, the company retained approximately 32 kroner in operating profit. This is a very high profitability for a company that is simultaneously growing so fast. Reported revenue growth was +19.5 % and without this currency effect, growth was +27.5 %. For Medistim's own products: +33.6 %. Medistim normally earns better on its own products than on products it only distributes for others. Thus, it is particularly positive that it is its own products that are driving the growth. ---------------------------------------------------------------- 2. USA is the big growth engine USA: +46.3 %, EU: +19.4 %, Asia: +22.4 % America already accounted for 103.7 mill. kroner. The American growth of 46 % largely came from price increases. Management indicated approximately: +37 percentage points from price +9 percentage points from volume The number of American flow procedures increased: +32.8 % to 27 148 procedures. Procedures related to PPP cards/rental agreements increased by as much as: +48.1 %. Total number of flow and imaging procedures increased: +27.2 % - My comment: This shows that Medistim has very strong pricing power. Customers seem to accept higher prices. But the volume figures in the USA are actually good. This means that it's not just about Medistim demanding more money for the same products. The use of the products is also increasing sharply. ------------------------------------------------------------------ 3. Around 70 % of sales are recurring Approximately 70 % of revenue in the last 12 months comes from recurring sales, including probes, PPP cards, and leasing-related revenues. A hospital doesn't just buy one Medistim machine and then the customer relationship is over. When the machines are used in operations, customers need consumables and probes, among other things. - My comment: This makes revenues more predictable than for a company that constantly has to find new customers to sell new equipment. --------------------------------------------------------------------- 4. First half 2026 H1 2025 had an EBIT margin of around 32.3 %, while H1 2026 is at: 30.3 % - My comment: Why has the H1 margin fallen? The company has hired more employees, is spending more money on marketing and customer relations, has built up its own organization in Japan with around 10 employees, is migrating IT systems to the cloud, and has incurred US customs costs. Customs alone cost approximately 5 mill. kr in Q2 and 10 mill. kr in H1. The positive thing is that despite this, the company managed a Q2 EBIT margin of 32.3 %. -------------------------------------------------------------------- 5. The Balance Sheet At the end of June, Medistim had: Cash: 100.1 mill. kr Interest-bearing bank debt: 0 kr Equity ratio: 70.6 % ------------------------------------------------------------------- 6. The Cash Flow Operating cash flow in Q2 is 47.8 mill. kr, compared to 37.7 the year before. ------------------------------------------------------------------ 7. More growth drivers are coming The INTUI software will be extended to Vascular and Ultimate systems in the first half of 2027. New MiraQ Ultimate and MiraQ Vascular are expected to be launched in Q2 2027. Japan has just switched to direct sales through Medistim's own organization. China is normalizing after the transition from distributor to direct sales. The PATENT study and SMARTFLOW study can contribute to further clinical documentation and market penetration. My comment: This means that growth is not only dependent on current products. ------------------------------------------------------------------ 7. What does management say? Management says that the new plan entails a higher growth trajectory than the company has had in the last five years, while also expecting further margin improvement over time. They now believe that the company can reach 1 billion kroner in annual revenue in just a few years. In comparison, 2025 revenue was 699.8 mill. -My comment: This means that the company still sees significant growth ahead. This is important because we are talking about a company that already has a relatively high market share in several areas.
·1 päivä sittenWow, Medistim delivers again!! New quarter with good growth on all fronts. 19.5% top-line growth compared to Q2/25 in NOK, adjusted for currency, the growth is a full 27.5%; 46.3% growth in America, 19.4% growth in Europe and 22.4% growth in Asia. In other words, it's going incredibly well!. EBIT of NOK 65.3m is also 20.6% higher than the same quarter last year. Good cash flow and cash position; with quarterly dividends on the way, the dividend capacity is now approx NOK 3 per quarter, which gives a div-yield of around 5% at today's share price; very good for a company that has zero debt and that grows 15-25% p.a. The share price is still 6% below the level from a year ago, and 40% below ATH in 2021.
This was beyond all expectations, if you ask me. The company is valued at 25 times 2026 earnings, guides increased growth in the coming years and further margin expansion. On top of this: no interest-bearing debt and good cash + quarterly dividends. A bargain at this price
·14.8.What happened now then?It was a large buy order that moved the price up. It looks like the order was institutional, like a fund or someone who knows more than you and I. They have positioned themselves before the Q2 report, and it smells like they know something...😉
·16.7.Medistim is in a rising trend channel in the medium term. Rising trends indicate that the company is undergoing positive development and that investor buying interest is increasing. The stock has broken a rectangle formation. An established break of resistance at 233 kroner will signal further upside to 239 kroner or more. The stock has broken up through resistance at approximately 227 kroner. Further upside is thus signaled, and there is now support at 227 kroner on pullbacks. Volume has previously been low around price tops and high around price bottoms. This weakens the rising trend and could be an early signal of an upcoming trend break. The RSI curve shows a rising trend, which supports the positive trend picture. Overall, the stock is considered technically positive in the medium term. Recommendation: BuyUnsure how effective TA is for a company with such low stock liquidity as Medistim. That being said, I don't disagree with the conclusion. The company has now beaten expectations 5 quarters in a row, it will be exciting to see the Q2 results coming on August 19. I believe there is such good momentum in revenue growth that we could quickly see another quarter with a positive surprise. I'm guessing we could then quickly establish a new level for the stock >250!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧49 min
8,00 NOK/osake
Viimeisin osinko
3,43%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23 t sittenI have been following Medistim for a while. I once shared my fundamental analysis here on May 18 (see at the bottom of the posts). In my fundamental analysis, I applied Warren Buffett-inspired criteria for a healthy and profitable company. Medistim was the only one among all listed companies in the Nordics that met the criteria. Once again, after the Q2 report, we have the evidence that Medistim is a true quality company that hasn't been fully discovered yet, but it's only a matter of time. I went through the fresh report, and here is my new analysis: 1. Q2 result Revenue: 202 mill. (169.1) -> +19.5 % (Currency-adjusted revenue growth: +27.5 %) EBIT: 65.3 mill. (54.1) -> +20.6 % EBIT margin: 32.3 % Profit after tax: 52.2 mill.(42.9) -> +21.6 % EPS: 2.85 kr Gross margin: 82.2 % - My comment: For every 100 kroner in revenue, the company retained approximately 32 kroner in operating profit. This is a very high profitability for a company that is simultaneously growing so fast. Reported revenue growth was +19.5 % and without this currency effect, growth was +27.5 %. For Medistim's own products: +33.6 %. Medistim normally earns better on its own products than on products it only distributes for others. Thus, it is particularly positive that it is its own products that are driving the growth. ---------------------------------------------------------------- 2. USA is the big growth engine USA: +46.3 %, EU: +19.4 %, Asia: +22.4 % America already accounted for 103.7 mill. kroner. The American growth of 46 % largely came from price increases. Management indicated approximately: +37 percentage points from price +9 percentage points from volume The number of American flow procedures increased: +32.8 % to 27 148 procedures. Procedures related to PPP cards/rental agreements increased by as much as: +48.1 %. Total number of flow and imaging procedures increased: +27.2 % - My comment: This shows that Medistim has very strong pricing power. Customers seem to accept higher prices. But the volume figures in the USA are actually good. This means that it's not just about Medistim demanding more money for the same products. The use of the products is also increasing sharply. ------------------------------------------------------------------ 3. Around 70 % of sales are recurring Approximately 70 % of revenue in the last 12 months comes from recurring sales, including probes, PPP cards, and leasing-related revenues. A hospital doesn't just buy one Medistim machine and then the customer relationship is over. When the machines are used in operations, customers need consumables and probes, among other things. - My comment: This makes revenues more predictable than for a company that constantly has to find new customers to sell new equipment. --------------------------------------------------------------------- 4. First half 2026 H1 2025 had an EBIT margin of around 32.3 %, while H1 2026 is at: 30.3 % - My comment: Why has the H1 margin fallen? The company has hired more employees, is spending more money on marketing and customer relations, has built up its own organization in Japan with around 10 employees, is migrating IT systems to the cloud, and has incurred US customs costs. Customs alone cost approximately 5 mill. kr in Q2 and 10 mill. kr in H1. The positive thing is that despite this, the company managed a Q2 EBIT margin of 32.3 %. -------------------------------------------------------------------- 5. The Balance Sheet At the end of June, Medistim had: Cash: 100.1 mill. kr Interest-bearing bank debt: 0 kr Equity ratio: 70.6 % ------------------------------------------------------------------- 6. The Cash Flow Operating cash flow in Q2 is 47.8 mill. kr, compared to 37.7 the year before. ------------------------------------------------------------------ 7. More growth drivers are coming The INTUI software will be extended to Vascular and Ultimate systems in the first half of 2027. New MiraQ Ultimate and MiraQ Vascular are expected to be launched in Q2 2027. Japan has just switched to direct sales through Medistim's own organization. China is normalizing after the transition from distributor to direct sales. The PATENT study and SMARTFLOW study can contribute to further clinical documentation and market penetration. My comment: This means that growth is not only dependent on current products. ------------------------------------------------------------------ 7. What does management say? Management says that the new plan entails a higher growth trajectory than the company has had in the last five years, while also expecting further margin improvement over time. They now believe that the company can reach 1 billion kroner in annual revenue in just a few years. In comparison, 2025 revenue was 699.8 mill. -My comment: This means that the company still sees significant growth ahead. This is important because we are talking about a company that already has a relatively high market share in several areas.
- ·1 päivä sittenWow, Medistim delivers again!! New quarter with good growth on all fronts. 19.5% top-line growth compared to Q2/25 in NOK, adjusted for currency, the growth is a full 27.5%; 46.3% growth in America, 19.4% growth in Europe and 22.4% growth in Asia. In other words, it's going incredibly well!. EBIT of NOK 65.3m is also 20.6% higher than the same quarter last year. Good cash flow and cash position; with quarterly dividends on the way, the dividend capacity is now approx NOK 3 per quarter, which gives a div-yield of around 5% at today's share price; very good for a company that has zero debt and that grows 15-25% p.a. The share price is still 6% below the level from a year ago, and 40% below ATH in 2021.This was beyond all expectations, if you ask me. The company is valued at 25 times 2026 earnings, guides increased growth in the coming years and further margin expansion. On top of this: no interest-bearing debt and good cash + quarterly dividends. A bargain at this price
- ·14.8.What happened now then?It was a large buy order that moved the price up. It looks like the order was institutional, like a fund or someone who knows more than you and I. They have positioned themselves before the Q2 report, and it smells like they know something...😉
- ·16.7.Medistim is in a rising trend channel in the medium term. Rising trends indicate that the company is undergoing positive development and that investor buying interest is increasing. The stock has broken a rectangle formation. An established break of resistance at 233 kroner will signal further upside to 239 kroner or more. The stock has broken up through resistance at approximately 227 kroner. Further upside is thus signaled, and there is now support at 227 kroner on pullbacks. Volume has previously been low around price tops and high around price bottoms. This weakens the rising trend and could be an early signal of an upcoming trend break. The RSI curve shows a rising trend, which supports the positive trend picture. Overall, the stock is considered technically positive in the medium term. Recommendation: BuyUnsure how effective TA is for a company with such low stock liquidity as Medistim. That being said, I don't disagree with the conclusion. The company has now beaten expectations 5 quarters in a row, it will be exciting to see the Q2 results coming on August 19. I believe there is such good momentum in revenue growth that we could quickly see another quarter with a positive surprise. I'm guessing we could then quickly establish a new level for the stock >250!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 23.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 |
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 23.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 24.10.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 |
8,00 NOK/osake
Viimeisin osinko
3,43%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23 t sittenI have been following Medistim for a while. I once shared my fundamental analysis here on May 18 (see at the bottom of the posts). In my fundamental analysis, I applied Warren Buffett-inspired criteria for a healthy and profitable company. Medistim was the only one among all listed companies in the Nordics that met the criteria. Once again, after the Q2 report, we have the evidence that Medistim is a true quality company that hasn't been fully discovered yet, but it's only a matter of time. I went through the fresh report, and here is my new analysis: 1. Q2 result Revenue: 202 mill. (169.1) -> +19.5 % (Currency-adjusted revenue growth: +27.5 %) EBIT: 65.3 mill. (54.1) -> +20.6 % EBIT margin: 32.3 % Profit after tax: 52.2 mill.(42.9) -> +21.6 % EPS: 2.85 kr Gross margin: 82.2 % - My comment: For every 100 kroner in revenue, the company retained approximately 32 kroner in operating profit. This is a very high profitability for a company that is simultaneously growing so fast. Reported revenue growth was +19.5 % and without this currency effect, growth was +27.5 %. For Medistim's own products: +33.6 %. Medistim normally earns better on its own products than on products it only distributes for others. Thus, it is particularly positive that it is its own products that are driving the growth. ---------------------------------------------------------------- 2. USA is the big growth engine USA: +46.3 %, EU: +19.4 %, Asia: +22.4 % America already accounted for 103.7 mill. kroner. The American growth of 46 % largely came from price increases. Management indicated approximately: +37 percentage points from price +9 percentage points from volume The number of American flow procedures increased: +32.8 % to 27 148 procedures. Procedures related to PPP cards/rental agreements increased by as much as: +48.1 %. Total number of flow and imaging procedures increased: +27.2 % - My comment: This shows that Medistim has very strong pricing power. Customers seem to accept higher prices. But the volume figures in the USA are actually good. This means that it's not just about Medistim demanding more money for the same products. The use of the products is also increasing sharply. ------------------------------------------------------------------ 3. Around 70 % of sales are recurring Approximately 70 % of revenue in the last 12 months comes from recurring sales, including probes, PPP cards, and leasing-related revenues. A hospital doesn't just buy one Medistim machine and then the customer relationship is over. When the machines are used in operations, customers need consumables and probes, among other things. - My comment: This makes revenues more predictable than for a company that constantly has to find new customers to sell new equipment. --------------------------------------------------------------------- 4. First half 2026 H1 2025 had an EBIT margin of around 32.3 %, while H1 2026 is at: 30.3 % - My comment: Why has the H1 margin fallen? The company has hired more employees, is spending more money on marketing and customer relations, has built up its own organization in Japan with around 10 employees, is migrating IT systems to the cloud, and has incurred US customs costs. Customs alone cost approximately 5 mill. kr in Q2 and 10 mill. kr in H1. The positive thing is that despite this, the company managed a Q2 EBIT margin of 32.3 %. -------------------------------------------------------------------- 5. The Balance Sheet At the end of June, Medistim had: Cash: 100.1 mill. kr Interest-bearing bank debt: 0 kr Equity ratio: 70.6 % ------------------------------------------------------------------- 6. The Cash Flow Operating cash flow in Q2 is 47.8 mill. kr, compared to 37.7 the year before. ------------------------------------------------------------------ 7. More growth drivers are coming The INTUI software will be extended to Vascular and Ultimate systems in the first half of 2027. New MiraQ Ultimate and MiraQ Vascular are expected to be launched in Q2 2027. Japan has just switched to direct sales through Medistim's own organization. China is normalizing after the transition from distributor to direct sales. The PATENT study and SMARTFLOW study can contribute to further clinical documentation and market penetration. My comment: This means that growth is not only dependent on current products. ------------------------------------------------------------------ 7. What does management say? Management says that the new plan entails a higher growth trajectory than the company has had in the last five years, while also expecting further margin improvement over time. They now believe that the company can reach 1 billion kroner in annual revenue in just a few years. In comparison, 2025 revenue was 699.8 mill. -My comment: This means that the company still sees significant growth ahead. This is important because we are talking about a company that already has a relatively high market share in several areas.
- ·1 päivä sittenWow, Medistim delivers again!! New quarter with good growth on all fronts. 19.5% top-line growth compared to Q2/25 in NOK, adjusted for currency, the growth is a full 27.5%; 46.3% growth in America, 19.4% growth in Europe and 22.4% growth in Asia. In other words, it's going incredibly well!. EBIT of NOK 65.3m is also 20.6% higher than the same quarter last year. Good cash flow and cash position; with quarterly dividends on the way, the dividend capacity is now approx NOK 3 per quarter, which gives a div-yield of around 5% at today's share price; very good for a company that has zero debt and that grows 15-25% p.a. The share price is still 6% below the level from a year ago, and 40% below ATH in 2021.This was beyond all expectations, if you ask me. The company is valued at 25 times 2026 earnings, guides increased growth in the coming years and further margin expansion. On top of this: no interest-bearing debt and good cash + quarterly dividends. A bargain at this price
- ·14.8.What happened now then?It was a large buy order that moved the price up. It looks like the order was institutional, like a fund or someone who knows more than you and I. They have positioned themselves before the Q2 report, and it smells like they know something...😉
- ·16.7.Medistim is in a rising trend channel in the medium term. Rising trends indicate that the company is undergoing positive development and that investor buying interest is increasing. The stock has broken a rectangle formation. An established break of resistance at 233 kroner will signal further upside to 239 kroner or more. The stock has broken up through resistance at approximately 227 kroner. Further upside is thus signaled, and there is now support at 227 kroner on pullbacks. Volume has previously been low around price tops and high around price bottoms. This weakens the rising trend and could be an early signal of an upcoming trend break. The RSI curve shows a rising trend, which supports the positive trend picture. Overall, the stock is considered technically positive in the medium term. Recommendation: BuyUnsure how effective TA is for a company with such low stock liquidity as Medistim. That being said, I don't disagree with the conclusion. The company has now beaten expectations 5 quarters in a row, it will be exciting to see the Q2 results coming on August 19. I believe there is such good momentum in revenue growth that we could quickly see another quarter with a positive surprise. I'm guessing we could then quickly establish a new level for the stock >250!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt